Drug Topics
APRIL 15, 2025
Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, discusses effective strategies for balancing excellent patient care with strict regulations surrounding controlled substances.
Drug Topics
MARCH 24, 2025
Emily Leppien, PharmD, BCPS, BCPP, clinical associate professor of pharmacy practice at Binghamton University, discusses identifying potential red flags for substance use disorder.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The FDA Law Blog
MAY 19, 2025
Attorneys Office, Northern District of Illinois, April 21, 2025. While the presence of a dispensing red flag does not prohibit a pharmacist from filling a controlled substance, it means that there is a potential concern with the prescription, which the pharmacist must address andmake a record of its resolution, assuming it is resolvable.
PharmExec
DECEMBER 20, 2024
In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses the recent DEA extensions of telehealth for controlled substances and new treatment modalities or patient populations he anticipates will become more accessible through telehealth in 2025.
The FDA Law Blog
JUNE 3, 2025
Attorneys Office, Northern District of Illinois, April 21, 2025, quoted here. Press Release, Walgreens Agrees To Pay Up to $350M for Illegally Filling Unlawful Opioid Prescriptions and Submitting False Claims, U.S.
The FDA Law Blog
DECEMBER 12, 2024
The NPRM seeks to reschedule marijuana from schedule I of the federal Controlled Substances Act (CSA) to schedule III. Last weeks prehearing conference set the parameters for the hearing on the merits, scheduled to begin January 21, 2025. Prehearing Ruling (Dec. 4, 2024), at 1.
pharmaphorum
DECEMBER 14, 2022
Harmony Biosciences introduced Wakix to the market in 2019 as the first non-controlled substance for the treatment of narcolepsy. For Avadel’s Lumryz, the one-dose extended-release oral suspension that allows narcolepsy patients to sleep through the night, the worst-case scenario is it won’t be on the market until 2025.
Expert insights. Personalized for you.
247 
Let's personalize your content